+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating sacituzumab tirumotecan alone and in combination with pembrolizumab compared to the Treatment of Physicians Choice TPC in participants with hormone receptor positivehuman epidermal growth factor receptor-2 negative HRHER2- unresectable locally advanced or metastatic breast cancer. The study aims to determine if these treatments improve progression-free survival PFS based on standardized tumor response criteria, with a focus on participants who have progressed after endocrine therapy and are chemotherapy candidates. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given every two weeks by intravenous infusion until disease progression or stopping, sacituzumab tirumotecan plus pembrolizumab the latter given every six weeks by intravenous infusion for up to approximately two years, or a physicians choice of chemotherapy including options such as paclitaxel, nab-paclitaxel, capecitabine, or liposomal doxorubicin with varying dosing schedules. Treatments continue until disease progression or discontinuation. Throughout the study, participants undergo regular assessments including tumor imaging reviewed by a blinded independent central review to evaluate progression-free survival up to about 40 months. Additional measures include overall survival, response rates, quality of life questionnaires, and safety monitoring for adverse events over extended follow-up periods up to about 95 months. The study involves scheduled visits for treatment administration and monitoring, with data collected on health status, physical and emotional functioning, and treatment tolerability.

Age: 18Years +All GendersPhase 3
259 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of ifinatamab deruxtecan I-DXd in adults with various recurrent or metastatic solid tumors, including endometrial cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer, hepatocellular carcinoma, adenocarcinoma of the esophagus and stomach, urothelial carcinoma, ovarian cancer, cervical cancer, biliary tract cancer, HER2-low and HER2 IHC 0 breast cancer, cutaneous melanoma, and neuroendocrine carcinoma. The study is an open-label, phase 1B2 trial with multiple cohorts and includes a safety run-in phase for hepatocellular carcinoma participants. Participants receive I-DXd through intravenous infusions at a dose of 12 mgkg with a determined dose for hepatocellular carcinoma in repeated cycles. The trial is divided into three parts Stage 1, Stage 2, and an optional Stage 3 for the endometrial cancer cohort based on safety and efficacy data. Each cohort starts with Stage 1 and may progress to Stage 2 if criteria are met. The hepatocellular carcinoma cohort undergoes a safety run-in phase to assess tolerability. During the trial, participants will have tumor samples collected before treatment, imaging assessments to measure disease response, and regular monitoring for side effects and adverse events. Researchers will evaluate objective response rate, dose-limiting toxicities, treatment-emergent adverse events, duration of response, progression-free survival, disease control rate, overall survival, pharmacokinetics, and immune responses over a period of up to approximately 60 months. Participants will be followed closely through scheduled visits and tests throughout the study duration.

Age: 18Years +All GendersPhase 1Phase 2
120 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of nemtabrutinib in adults with various blood cancers including chronic lymphocytic leukemia CLL, small lymphocytic lymphoma SLL, Richters transformation, marginal zone lymphoma MZL, mantle cell lymphoma MCL, follicular lymphoma FL, and Waldenstrms macroglobulinemia WM. This phase 2 study is sponsored by Merck Sharp & Dohme LLC and involves two parts Dose Escalation and Confirmation Part 1 and Cohort Expansion Part 2, which includes eight disease-specific groups. Participants receive nemtabrutinib tablets orally once daily until their disease progresses or they discontinue the treatment. Part 1 focuses on finding the recommended dose and assessing safety, while Part 2 enrolls participants in specific cohorts based on their disease type and treatment history. Cohorts include various lymphoma and leukemia subtypes, with some requiring prior therapy history and measurable disease criteria. During the study, participants will be monitored regularly for side effects, disease response, and drug levels in the body. Assessments include imaging scans, biopsies, blood tests, and evaluations based on established lymphoma and leukemia criteria. The study measures outcomes such as dose-limiting toxicities, adverse events, treatment discontinuations, and objective response rates over periods ranging from weeks to several years. Participants may stay in the study for up to approximately 5 years, with ongoing monitoring to evaluate the treatments impact and safety.

Age: 18Years +All GendersPhase 2
121 locations
S

Actively Recruiting

Researchers are evaluating pembrolizumab combined with carboplatin and taxane chemotherapy followed by pembrolizumab with or without maintenance sacituzumab tirumotecan sac-TMT as a first-line treatment for metastatic squamous non-small cell lung cancer NSCLC. This phase 3 study aims to determine if adding maintenance sac-TMT improves overall survival compared to pembrolizumab alone. Participants first undergo an induction phase consisting of four cycles of pembrolizumab every three weeks, carboplatin every three weeks, and either paclitaxel every three weeks or nab-paclitaxel weekly. After induction, participants are randomly assigned to receive either pembrolizumab maintenance alone or pembrolizumab combined with sac-TMT maintenance. The maintenance phase involves pembrolizumab every six weeks for up to 96 weeks and sac-TMT infusions every two weeks until discontinuation criteria are met. Throughout the study, participants will have tumor assessments, scans, and evaluations to monitor disease status, side effects, and quality of life. Researchers will measure overall survival up to approximately 50 months and progression-free survival up to 79 months, along with patient-reported symptoms such as dyspnea, cough, and chest pain. Safety monitoring includes tracking adverse events and treatment discontinuations. The total participation may last several years as long-term outcomes are assessed.

Age: 18Years +All GendersPhase 3
217 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying the Turkish version of the General Sleep Disturbance Scale GSDS-T to evaluate its validity and reliability in patients with multiple sclerosis MS. The GSDS-T assesses difficulties falling asleep, waking during sleep, overall sleep quality, and daytime alertness. Although the scale has been validated in Turkish stroke patients, this study aims to confirm its accuracy specifically for MS patients. This observational study involves 126 participants diagnosed with MS. The GSDS-T, consisting of 21 questions, will be administered along with the Pittsburgh Sleep Quality Index PSQI, a validated Turkish tool for assessing sleep quality. To measure test-retest reliability, these scales will be repeated after 15 days. Participants will complete the sleep disturbance and sleep quality assessments at baseline and again two weeks later. The study monitors and compares these results to evaluate the GSDS-Ts consistency and accuracy in this population. The total participation timeline includes the initial assessment and a follow-up after 15 days to review changes or stability in responses.

Age: 18Years - 65YearsAll Genders
1 location
S

Actively Recruiting

Researchers are evaluating the combination of sacituzumab tirumotecan and pembrolizumab compared to pembrolizumab alone in treating people with metastatic non-small cell lung cancer NSCLC who have high levels of PD-L1 expression at least 50%. The study aims to see whether adding sacituzumab tirumotecan improves overall survival compared to pembrolizumab alone. This is a phase 3, randomized, open-label trial sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan plus pembrolizumab or pembrolizumab alone. Sacituzumab tirumotecan is given by intravenous infusion on Days 1, 15, and 29 of each 6-week cycle, while pembrolizumab is administered by intravenous infusion on Day 1 of each 6-week cycle for up to 18 cycles. Supportive medications such as diphenhydramine, an H2 antagonist, acetaminophen, and dexamethasone are given around the first four infusions of sacituzumab tirumotecan to help manage infusion reactions. During the study, participants undergo assessments including overall survival, progression-free survival, response rates, and quality of life measured by validated questionnaires. Safety is monitored throughout the treatment period and beyond. The study tracks symptoms like cough, chest pain, and breathing difficulties, along with adverse events and treatment discontinuations. The total follow-up for outcomes may extend up to approximately 77 months, allowing for long-term monitoring of treatment effects and safety.

Age: 18Years +All GendersPhase 3
220 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of two different doses of inavolisib combined with fulvestrant in adults with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer who have previously been treated with cyclin-dependent kinase inhibitors. This phase II trial aims to compare these combinations to better understand their impact on this specific breast cancer type. Participants will receive oral inavolisib tablets alongside fulvestrant administered by intramuscular injection. The study involves two experimental groups, each receiving a different dose level of inavolisib combined with fulvestrant. Treatments are given according to a schedule defined in the study protocol, and participants are randomly assigned to one of these groups. During the trial, participants will undergo evaluations to measure tumor response and monitor any side effects over approximately two years. Researchers will track outcomes such as objective response rate, duration and time to response, progression-free survival, and treatment-related adverse events. Patient-reported outcomes concerning symptoms and quality of life will also be collected. Safety monitoring will continue throughout the treatment and follow-up periods to assess the impact of the study drugs.

Age: 18Years +All GendersPhase 2
34 locations
S

Actively Recruiting

Researchers are evaluating the Turkish version of the Situational Vertigo Questionnaire SVQ to determine its validity and reliability for assessing dizziness symptoms often triggered by visual or environmental factors in people with vestibular conditions. The study is designed as a methodological scale adaptation and psychometric evaluation involving adults aged 18 and older who experience situational dizziness and can read Turkish. The Turkish adaptation process involves a detailed back-and-forth translation method to ensure linguistic and cultural accuracy. After developing a preliminary Turkish version, a pilot test with 20 participants will assess clarity, followed by revisions as needed. The final version will be used in a larger group to evaluate its psychometric properties. Participants will complete the SVQ along with other assessments such as the Dizziness Handicap Inventory DHI, Vertigo Symptom Scale VSS, and a Visual Analog Scale VAS for satisfaction. A subgroup will retake the SVQ after 7-14 days to assess test-retest reliability. Participants will provide written consent and complete surveys on their dizziness symptoms and related factors like medical history and daily activities. Researchers will collect detailed sociodemographic and clinical data to support analysis. No invasive procedures are involved. The main outcome measure is the SVQ score at baseline and follow-up, with secondary measures including DHI and VSS scores. Data confidentiality will be maintained, and findings are expected to support clinical evaluations by providing a reliable dizziness assessment tool in Turkish.

Age: 18Years +All Genders
1 location